Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $71,904.30 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 2,685 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $71,904.30. Following the completion of the sale, the insider owned 147,499 shares in the company, valued at approximately $3,950,023.22. This trade represents a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $26.77 on Friday. The company’s 50-day moving average price is $22.14 and its 200-day moving average price is $17.76. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $26.85. The company has a quick ratio of 5.10, a current ratio of 5.17 and a debt-to-equity ratio of 8.18. The company has a market cap of $1.43 billion, a PE ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. On average, equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on KALV shares. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Stifel Nicolaus boosted their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $30.60.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of KALV. Parallel Advisors LLC boosted its holdings in KalVista Pharmaceuticals by 45.8% during the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 589 shares during the period. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $55,000. Royal Bank of Canada boosted its stake in shares of KalVista Pharmaceuticals by 137.0% during the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares during the period. Finally, Truvestments Capital LLC boosted its stake in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.